Leptin-induced migration and angiogenesis in rheumatoid arthritis is mediated by reactive oxygen species

Xiaotong Sun1,*, Jing Wei1,*, Yawei Tang1, Bing Wang1, Yan Zhang2, Lei Shi3, Jianping Guo4, Fanlei Hu4 and Xia Li1

1 Department of Immunology, College of Basic Medical Science, Dalian Medical University, Liaoning, China
2 Department of Rheumatology and Immunology, The Second Affiliated Hospital of Dalian Medical University, Liaoning, China
3 College of Basic Medical Science, Dalian Medical University, Liaoning, China
4 Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China

Keywords
angiogenesis; leptin; migration; reactive oxygen species; rheumatoid arthritis

Correspondence
X. Li, Department of Immunology, College of Basic Medical Science, Dalian Medical University, Lushun South Road, Dalian 116044, China
Tel: +86 411 86110346
E-mail: lixia0416@dlmedu.edu.cn

*These authors contributed equally to this work.

(Received 18 May 2017, revised 3 September 2017, accepted 20 September 2017)

doi:10.1002/2211-5463.12326

Rheumatoid arthritis (RA) is a progressive autoimmune disease affecting the joints. In this study, we investigated the role of the pro-angiogenic factor leptin in regulating reactive oxygen species (ROS) to promote cell migration and angiogenesis in RA. We showed that leptin triggered RA fibroblast-like synoviocyte (FLS) migration by increased ROS expression. Additionally, leptin enhanced human umbilical vein endothelial cell (HUVEC) tube formation in a ROS/hypoxia-inducible factor-1α-dependent manner, accompanied by increased production of vascular endothelial growth factor and interleukin (IL)-6. We also revealed that antagonists of tumor necrosis factor, IL-6 and IL-1β down-regulated ROS production of RA FLS induced by leptin, which subsequently attenuated RA FLS migration and HUVEC tube formation. These findings demonstrated that leptin might play an important role in RA FLS migration and HUVEC angiogenesis.

Rheumatoid arthritis (RA) is a progressive autoimmune disease associated with synovial hyperplasia, pannus formation and synovial inflammation of multiple joints, which leads to disruption of joint cartilage, bone loss and the disease spreading into normal joints. Number of cell populations including T cells, B cells, macrophages and fibroblast-like synoviocytes (FLSs) are activated in the pathogenesis of RA. However, FLSs are the primary effector cells of synovial hyperplasia and are the main origin of inflammatory mediators resulting in the initiation and development as well as the joint destruction of RA [1].

Since synovial hyperplasia and pannus formation are involved in the unique clinical characteristics of RA, some correlative biological behaviors of FLSs thought to bear on the course of RA. Firstly, the abnormal migration of RA FLSs were found to be responsible for joint inflammation and destruction in RA [1]. Eisinger et al. [2] have already addressed the migratory potential of FLSs that favors their shifting

Abbreviations
CM, conditioned medium; DCFHDA, 2',7'-dichlorofluorescein diacetate; DPI, diphenyleneiodonium chloride; FACS, fluorescence-activated cell sorting; FLS, fibroblast like synoviocyte; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HIF-1α, hypoxia-inducible factor-1α; HUVEC, human umbilical vein endothelial cell; IL-1βR, IL-1β receptor; IL-6R, IL-6 receptor; IL, interleukin; NAC, N-acetyl-L-cysteine; RA, rheumatoid arthritis; ROS, reactive oxygen species; TNFR, tumor necrosis factor receptor; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
to a distant unaffected joint and then eventually to the majority of joints. Secondly, RA FLSs in particular represent a major effector in the invasive pannus. Angiogenesis is a key aspect in pannus formation, and was modulated by vascular endothelial growth factor (VEGF) as well as its receptor, which favored blood vessel formation and immersion of leukocytes into synovial tissues of unaffected joint [3]. It has also been documented that the expression of hypoxia-inducible factor (HIF)-1α, a cardinal transcription factor of VEGF [4], was elevated in RA FLSs with the stimulation of interleukin (IL)-1 or tumor necrosis factor (TNF)-α [5], indicating the unique role of FLSs in generating and maintaining the pannus in RA. So it has become widely held that regulation of the migratory and angiogenic actions of FLSs might be a promising treatment strategy for RA.

There are many factors promoting the migration of FLSs, such as histamine [6], protein arginine methyl-transferase 5 [7], growth differentiation factor 9 [8], Toll-like receptor 2 [9] and placental growth factor [10]. Leptin, initially identified as a pro-angiogenic factor [11], participate in numerous biological processes. The functional leptin receptor is expressed in many cells, including vascular smooth muscle cells, endothelial cells and T lymphocytes. Thus, leptin is known to have multiple effects in promoting vascular remodeling, atherosclerosis and, more recently, angiogenesis [12]. It was also documented that leptin elevated VEGF expression and promoted angiogenesis in human chondrosarcoma cells [13]. Gonzalez-Perez et al. [14] provided evidence on leptin signaling in the modulation of VEGF promoting tumor angiogenesis, and focused on the idea that leptin could trigger angiogenesis, growth and survival of breast cancer cells. Meanwhile emerging evidence indicated that leptin could up-regulate the secretion of inflammatory cytokines including TNF-α, IL-6 and IL-12 in RA patients [15–17]. Our previous work (M. Wang, J. Wei, H. Li, X. Ouyang, X. Sun, Y. Tang, B. Wang, X. Li, unpublished data) illustrated that concentrations of leptin, positively related to the disease activity, were elevated in the serum of RA patients. In this study, we concentrated on whether leptin plays a role on the migration of RA FLSs and angiogenesis in RA patients.

Materials and methods

Patients and tissue specimens

Rheumatoid arthritis FLSs were isolated by enzymatic digestion of synovial tissues obtained from eight RA patients (F/M 6/2, median age 54 (range: 38–61) years, median duration 7.5 (range: 3–16) years undergoing total joint replacement surgery. The rheumatoid factors were positive in seven patients. Erythrocyte sedimentation rate and anti-cyclic citrullinated peptide antibody checked pre-operatively had median values of 54 (range: 25–84) mm h⁻¹ and 55 (range: 35–136) U·mL⁻¹, respectively. All RA patients in this study fulfilled the American College of Rheumatology 2009 criteria for RA.

The tissues were minced after washing with PBS and digested with type I collagenase (Sigma-Aldrich, St Louis, MO, USA) in Dulbecco’s modified Eagle’s medium (DMEM) for 2 h at 37 °C in 5% CO₂. The study was agreed by the ethics committee of the Second Hospital of Dalian Medical University.

Cell culture and treatment

Rheumatoid arthritis FLSs were cultured in DMEM supplemented with 10% FBS (Thermo Fisher Scientific, Waltham, MA, USA), and cell lines were used from three to five passages in this experiment. Human umbilical vein endothelial cell (HUVECs) were cultured in M199 medium (Gibco). All cells were cultured in medium supplemented with penicillin (50 U·mL⁻¹) and streptomycin (50 µg·mL⁻¹) and maintained in an incubator with 5% CO₂ at 37 °C.

In some experiments, RA FLSs were stimulated with leptin after being preincubated with 2-methoxyestradiol (a HIF-1α inhibitor; Selleck, Houston, TX, USA), N-acetyl-l-cysteine (NAC; Sigma-Aldrich) and diphenyleneiodonium chloride (DPI; Sigma-Aldrich). After 24 h incubation, culture supernatants were measured by ELISA. In other experiments, RA FLSs were pretreated with block antibodies of tumor necrosis factor receptor (TNFR) 2, IL-6 receptor (IL-6R) and IL-1β receptor (IL-1βR) (R&D Systems, Minneapolis, MN, USA) before being incubated with leptin. Detection of RA FLS migration, reactive oxygen species (ROS) level and HUVEC tube formation was performed as described below.

Quantitative RT-PCR

Total RNA was extracted from cells from six RA patients using RNAiso Plus (Takara Bio, Dalian, China) according to the manufacturer’s instructions. The primers (Takara Bio) used to amplify genes were as follows: for HIF-1α: 5′-CTCAAGTCGGACAGCCTCA-3′ (forward), 5′-CCCTGCAGTAGGTTCGTGCT-3′ (reverse); glyceraldehyde 3-phosphate dehydrogenase (GAPDH): 5′-TGACCA-CAGTCCATGCCATC-3′ (forward), 5′-CGCTTCGCC TTCACCACCTTCT-3′ (reverse). Gene expression was quantified relative to the expression of the housekeeping gene GAPDH and normalized to control by standard 2⁻ΔΔCT calculation.
ELISA assay

Supernatants from eight patients’ RA FLSs were used for ELISA. ELISA kits were used for detecting the concentration of cytokines in the supernatants according to the manufacturers’ instructions as follows: VEGF, IL-1β and TNF-α ELISA kits from SenBioDia Bio (Nanjing, China) and IL-6 ELISA kit from BioLegend (San Diego, CA, USA).

Quantification of ROS levels

2′,7′-Dichlorofluorescein diacetate (DCFHDA; Sigma-Aldrich), a membrane-permeant probe, was used to detect intracellular ROS level. Six RA patients’ cells were used for ROS detection. After the addition of leptin for 1 h, RA FLSs were incubated with DCFHDA in serum-free medium at 37 °C for 30 min. After washing twice with PBS, mean fluorescence intensity was determined and analyzed with a flow cytometer (Accuri C6; BD Biosciences, San Jose, CA, USA) at an excitation wavelength of 488 nm and an emission wavelength of 538 nm. Cells were observed under a microscope with a ×100 magnification.

Scratch assay

RA FLSs from six patients were used for a scratch assay. RA FLSs were drawn into a six-well plate after 24 h at a confluence of 80%. Next, scratches were made in each well using a 200 μL pipette tip and replaced with serum-free DMEM. The widths of wound at 0 and 24 h were determined from images obtained with an inverted microscope (Olympus 1X71, Tokyo, Japan) and evaluated by measuring the distance of the wound region in the absence of cells.

Transwell migration assay

Rheumatoid arthritis FLSs from six patients were used for a Transwell migration assay. Cell migration was performed by using Transwell chambers (8 μm pores; Corning, New York, USA) in 24-well plates. RA FLSs were added into the upper chambers and the lower chambers were filled with DMEM containing 10% FBS as the chemoattractant. After 24 h incubation, unmigrated cells in the upper chamber were removed, and the migrated cells on the lower side of the membranes were immersed into methanol for 10 min and stained with 0.1% crystal violet. Images were taken using an inverted microscope. Migrated cells were counted from five random fields (×100 magnification).

HUVEC tube formation assay

Supernatants from six RA patients treated with vehicle or leptin for 24 h were collected and stored at −20 °C before using. Next, growth factor reduced Matrigel (BD Biosciences) was added into 48-well plates (100 μL each) for gelatinizing at 37 °C for 30 min. Serum-starved HUVECs were removed and resuspended in a 1 : 1 mixture of RA FLS culture supernatants and 1% FBS DMEM (total 200 μL) and then plated on the top of the Matrigel at 37 °C. Tube formation was observed every hour after cell seeding. Representative photos were taken at 8 h with an inverted microscope (×100 magnification) and the number of lengthened tubes were quantified using ImageJ software (NIH, Bethesda, MD, USA).

Flow cytometry analysis

Six RA patients’ cells were used for HIF-1α protein measurement. After RA FLSs were treated with leptin for 4 h, the cells were fixed and permeabilized, then stained using phycoerythrin-conjugated anti-HIF-1α (R&D Systems). Mean fluorescence intensity was analyzed with a flow cytometer (Accuri C6; BD Biosciences).

Statistics

spss V.17.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Statistical analysis was carried out using Wilcoxon’s signed-rank test or one-way ANOVA. A P-value of < 0.05 was considered statistically significant.

Results

Leptin triggered RA FLS migration and promoted HUVEC tube formation

Rheumatoid arthritis FLSs have tumor-like characteristics including migration and angiogenesis, which may be caused by chronic exposure to a variety of stimuli. Leptin has been reported to increase cell migration and angiogenesis in some types of cancer cells and myelomonocytic cells [18,19]. In this study, we wanted to know whether leptin can promote RA FLS migration and HUVEC tube formation.

First, we explored the influence of leptin on RA FLS migration. Scratch assays and Transwell migration assays were performed after leptin had stimulated RA FLSs for 24 h. As shown in the scratch assay, leptin-treated RA FLSs were more likely to migrate into the created cell-free area than untreated FLSs. Subsequently, FLS migration was determined by a Transwell migration assay. RA FLSs treated with leptin exhibited strong upregulation of migration compared with the control group (*P ≤ 0.05; Fig. 1A).

Angiogenesis has been considered to be a critical step in the initiation and progression of chronic arthritis [20]. RA FLSs, as important inflammatory cells, can release proangiogenic growth factors including VEGF...
and IL-6, which facilitate neovascularization. Here we observed tube formation of HUVECs that were treated with conditioned medium (CM) derived from leptin-stimulated RA FLSs or untreated RA FLSs. As we expected, leptin-treated CM induced much more tube formation than vehicle-treated CM (*P ≤ 0.05; Fig. 1B). We also found that leptin-stimulated RA FLSs had markedly increased levels of VEGF and IL-6 in culture supernatants (**P ≤ 0.01; Fig. 1C).

**ROS production was involved in leptin-induced RA FLS migration and HUVEC tube formation**

Studies have shown that IL-1β induces endothelial cell angiogenesis by upregulating fibroblast growth factor 2 accompanied with increased ROS production [21], which suggests that ROS might be related to the angiogenesis process. First, to evaluate the effects of leptin on ROS generation by RA FLSs, cells were incubated with or without leptin for 24 h, and the intracellular ROS level was determined with the DCFHDA fluorescent probe. The result showed a remarkable increase in DCFHDA fluorescence in leptin-treated RA FLSs using fluorescence-activated cell sorting (FACS) and immunofluorescence analysis (*P ≤ 0.05; Fig. 2A). Next, to determine whether ROS took part in leptin-induced FLS migration and HUVEC tube formation, NAC (a ROS scavenger) and DPI (a ROS inhibitor) were used to block the effect of ROS. Pretreatment of RA FLS with NAC and DPI significantly attenuated leptin-triggered RA FLS migration (**P ≤ 0.01; Fig. 2B). Furthermore, the tube formation stimulated by leptin-treated CM was significantly inhibited by pretreatment with NAC and DPI (**P ≤ 0.01; Fig. 2C) and the levels of VEGF and IL-6 were also decreased (*P ≤ 0.05, **P ≤ 0.01; Fig. 2D,E). The results suggest that ROS production of leptin-stimulated RA FLSs was involved in RA FLS migration and HUVEC tube formation.

**ROS-mediated leptin-induced HUVEC tube formation via the activation of the HIF-1α pathway**

To further explore the mechanisms of leptin-induced HUVEC tube formation, we also examined the activation of HIF-1α, a related transcription factor that regulates VEGF expression by binding to hypoxia-response element. First, we explored the effect of leptin on HIF-1α expression of RA FLSs. The results from
qPCR and FACS indicated that HIF-1α mRNA expression and protein level were significantly increased in leptin-treated RA FLSs (\(**P \leq 0.01\); Fig. 3A). Next, further analysis showed that leptin-mediated HIF-1α expression could be markedly abrogated by NAC and DPI (\(**P \leq 0.01\); Fig. 3A), which indicated that leptin promoted HIF-1α expression on RA FLS via ROS production. Moreover, ELISA demonstrated that leptin-induced VEGF and IL-6 levels could be reduced by HIF-1α inhibitor treatment (2-methoxyestradiol; \(***P \leq 0.001\); Fig 3B). These results indicated that leptin-induced HIF-1α expression might serve as the downstream effector of ROS, which promoted VEGF and IL-6 production in RA FLSs.

Effect of antagonists of TNFR2, IL-6R and IL-1βR on ROS generation, RA FLS migration and HUVEC tube formation

The blockades of TNF, IL-6 and IL-1 are widely used in clinical RA treatment and are beneficial in ameliorating disease and controlling symptoms. Can antagonists of these cytokines influence RA FLS migration and HUVEC tube formation by down-regulating leptin-induced ROS production? We preincubated anti-TNFR2, anti-IL-6R and anti-IL-1βR with leptin-stimulated RA FLSs separately. A decline in ROS generation (\(**P \leq 0.01\); Fig. 4A, B), RA FLS migration (\(***P \leq 0.001\); Fig. 5A) and HUVEC tube formation (\(*P \leq 0.05\); Fig. 5B) was discovered in treatments with antagonists of TNFR2, IL-6R and IL-1βR.

Discussion

In the present study, we showed that leptin triggered RA FLS migration by increased ROS expression. Additionally, leptin enhanced HUVEC tube formation in a ROS/HIF-1α-dependent manner, accompanied by elevated VEGF and IL-6 production. We also revealed that antagonists of TNFR, IL-6R and IL-1βR down-regulated ROS production of RA FLSs induced by leptin, which subsequently attenuated RA FLS migration and HUVEC tube formation.
Rheumatoid arthritis is mainly characterized by synovial hyperplasia, activation of inflammatory cells and synovium invasion [22]. RA FLSs, as key players in joint destruction and migration, have been shown to contribute to the formation of invasive pannus through migrating to locally adjacent joints susceptible

Fig. 3. The ROS/HIF-1α pathway participated in leptin-induced HUVEC tube formation. (A) RA FLSs were pretreated with NAC and DPI for 1 h and then stimulated with leptin (100 ng·mL⁻¹) for 4 h. HIF-1α mRNA expression of RA FLSs was determined by real-time PCR. GAPDH was used as a control in real-time PCR. FACS was used to detect HIF-1α protein level (n = 6). (B) RA FLSs were preincubated with 10 μM 2-methoxyestradiol (a HIF-1α inhibitor) for 1 h and then stimulated with leptin (100 ng·mL⁻¹) for 24 h. The levels of VEGF and IL-6 in the supernatant were examined by ELISA (n = 8). All experiments were repeated three times. Data represent the mean ± SEM (one-way ANOVA; **P < 0.01, ***P < 0.001).

Fig. 4. ROS production was decreased by antagonists of TNF, IL-6 and IL-1β. RA FLSs were incubated with anti-TNFR2 (0.25 μg·mL⁻¹), anti-IL-6R (0.5 μg·mL⁻¹) and anti-IL-1βR (0.5 μg·mL⁻¹) for 2 h and then cultured with leptin (100 ng·mL⁻¹) for 1 h. ROS production was measured by flow cytometry (A) and immunofluorescence (B) (n = 6). All experiments were repeated three times. Data represent the mean ± SEM (one-way ANOVA; **P < 0.01).
to matrix destruction and even to distant unaffected joints through the bloodstream [23]. Several inflammatory factors such as IL-21 have been reported to promote RA FLS migration and invasion by upregulating matrix metalloproteinase in the phosphoinositide 3-kinase–signal transducer and activator of transcription-3 pathway [24]. Angiogenesis is the outgrowth and proliferation of capillaries from pre-existing blood vessels. In RA, the formation of new blood vessels provides oxygen and nutrients to the hypertrophic joint and supports the elevated transendothelial leukocyte infiltration that promotes synovial inflammation and bone destruction [20]. During active disease, RA FLSs are triggered by inflammatory mediators to produce proangiogenic growth factors and cytokines such as VEGF and IL-6. VEGF is a key regulator in the starting phase of angiogenesis, while IL-6 plays a central role in RA angiogenesis through both its direct effect on endothelial cells and its indirect effect on different cell types in RA synovium to produce proangiogenic factors [22]. Kayakabe et al. [25] proved that IL-6 was capable of inducing VEGF production in a co-culture system of RA FLSs and endothelial cells.

Leptin is one of the most important hormones secreted by adipose tissue and it regulates appetite, bone mass, basal metabolism, reproductive function and insulin secretion by binding and activating the long form of leptin receptor [26]. Recent studies showed that leptin signaling increased cell proliferation in breast cancer, led to cells evading apoptosis and induced angiogenesis [13,27,28]. The latest findings emphasize the role of leptin in the autoimmune and inflammatory rheumatic diseases, such as RA [29,30]. Plasma leptin levels correlated with 28-joint disease activity score and IL-17 in RA patients with conventional pharmacological treatment, which suggested that leptin could be a biomarker of long-term disease [31]. Our previous study showed that leptin could increase peripheral CD4+CXCR5+ICOS+ T cell numbers in RA patients (data not shown). In this study, we demonstrated that leptin promoted RA FLS migration and leptin-treated RA FLS CM facilitated HUVEC capillary-like structure formation, accompanied by the up-regulation of VEGF and IL-6 levels.

Hyperplasia of RA FLSs leads to over-proliferation of synovial tissue, which results in increased oxygen consumption in synovium and thereby forms a hypoxic environment. Hypoxia is essential for the inflammation, angiogenesis and cartilage degradation of RA and is associated with the generation of ROS. Accumulating evidence has shown that excess production of ROS is associated with cell migration, inflammation and apoptosis. In the present study, we found leptin-
induced ROS expression markedly promoted RA FLS migration. However, the master regulators of the immune response to oxygen tension are HIFs, levels of which are sensitive to oxygen tension changes [32,33]. HIF-1 is a heterodimeric transcription factor composed of HIF-1α, which is oxygen-regulated, and HIF-1β, which is expressed constitutively in nuclei. A study has shown that the increase of cellular ROS generation amplified HIF-1α stabilization and HIF-dependent expression of genes such as that for VEGF [34]. Here, we found that leptin-stimulated HIF-1α expression was mediated by ROS accompanied with increased VEGF and IL-6 levels. Taken together, these findings indicated that HIF-1α was a downstream regulator of leptin-induced ROS production, which regulated angiogenesis via up-regulating VEGF and IL-6 expressions.

Inflammatory cytokines such as TNF-α, IL-6 and IL-1 are important mediators in driving inflammation and joint destruction in RA. TNF and IL-1 stimulate synoviocytes and chondrocytes to release matrix metalloproteinases and other proteinases, and up-regulate the expression of proinflammatory genes, resulting in elevated production of various proinflammatory mediators [35,36]. IL-6 promotes survival of B cells and their differentiation into autoantibody-secreting long-lived plasma cells leading to RA joint destruction [37]. TNF, IL-6 and IL-1β blocking agents in RA patients resulted in a decline in disease severity and relief of arthritis symptoms. In this study, we have shown that antagonists of TNF, IL-6 and IL-1 could down-regulate leptin-induced ROS production and attenuate RA FLS migration and angiogenesis, which might offer a promising mechanism for clinical treatment of RA.

In summary, our findings clearly demonstrated that leptin induced RA FLS migration and promoted HUVEC tube formation through the activation of the ROS/HIF-1α signaling pathway. This study suggested that leptin inhibition could be a potential therapeutic target for the prevention of joint invasion and angiogenesis in RA. However, the mechanisms of how leptin promoted RA FLS migration and angiogenesis need further exploration.

Acknowledgements

This work was supported by National Natural Science Foundation of China (No. 81373214 and 81671606); a Special Grant for Translational Medicine, Dalian Medical University (2015010); and Flying aid program foundation of College of Basic Medical Science, Dalian Medical University.

Author contributions

XS and JW planned the experiments, performed the experiments, analyzed the data and wrote the manuscript. YT, YZ, BW, LS, JG and FH interpreted the experiments and analyzed the data. XL planned the experiments, analyzed data, modified the paper and approved the final version of the manuscript submitted for publication.

References

1. Brennan FM and Mcinnes IB (2008) Evidence that cytokines play a role in rheumatoid arthritis. *J Clin Invest* **118**, 3537–3545.
2. Eisinger K, Bauer S, Schäffler A, Walter R, Neumann E, Buechler C, Müller-Ladner U and Frommer KW (2012) Chemerin induces CCL2 and TLR4 in synovial fibroblasts of patients with rheumatoid arthritis and osteoarthritis. *Exp Mol Pathol* **92**, 90–96.
3. Park SY, Lee SW, Kim HY, Lee WS, Hong KW and Kim CD (2015) HMGB1 induces angiogenesis in rheumatoid arthritis via HIF-1α activation. *Eur J Immunol* **45**, 1216–1227.
4. Westra J, Molema G and Kallenberg CG (2010) Hypoxia-inducible factor-1 as regulator of angiogenesis in rheumatoid arthritis-therapeutic implications. *Curr Med Chem* **17**, 254–263.
5. Sun HL, Liu YN, Huang YT, Pan SL, Huang DY, Guh JH, Lee FY, Kao SC and Teng CM (2007) YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. *Oncogene* **26**, 3941–3951.
6. Qin Z, Fu Q, Zhang L, Yin H, Jin X, Tang Q, Lyu D and Yao K (2016) Proliferative effects of histamine on primary human pterygium fibroblasts. *Mediators Inflamn* **2016**, 1–10.
7. Chen D, Zeng S, Huang M, Xu H, Liang L and Yang X (2016) Role of protein arginine methyltransferase 5 in inflammation and migration of fibroblast-like synoviocytes in rheumatoid arthritis. *J Cell Mol Med* **21**, 781–790.
8. Jiang Z, Yu Q, Xia L, Zhang Y, Wang X, Wu X and Gao Z (2016) Growth differentiation factor-9 promotes fibroblast proliferation and migration in keloids through the Smad2/3 pathway. *Cell Physiol Biochem* **40**, 207–218.
9. McGarry T, Veale DJ, Gao W, Orr C, Fearon U and Connolly M (2015) Toll-like receptor 2 (TLR2) induces migration and invasive mechanisms in rheumatoid arthritis. *Arthritis Res Ther* **17**, 153–166.
10. Yoo SA, Park JH, Hwang SH, Oh SM, Lee S, Cicatiello V, Rho S, De Falco S, Hwang D, Cho CS et al. (2015) Placental growth factor-1 and -2 induce hyperplasia and invasiveness of primary rheumatoid synoviocytes. *J Immunol* **194**, 2513–2521.
Leptin induced migration and angiogenesis in RA

11 Sierra-Honigmann MR, Nath AK, Murakami C, García-Cardeúa G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwab MB, Polverini PJ et al. (1998) Biological action of leptin as an angiogenic factor. *Science* **281**, 1683–1686.

12 Ghantous CM, Azrak Z, Hanache S, Abou-Kheir W and Zeidan A (2015) Differential role of leptin and adiponectin in cardiovascular system. *Int J Endocrinol* **2015**, 534320.

13 Yang WH, Chen JC, Hsu KH, Lin CY, Wang SW, Wang SI, Chang YS and Tang CH (2014) Leptin increases VEGF expression and enhances angiogenesis in human chondrosarcoma cells. *Biochim Biophys Acta* **1840**, 3483–3493.

14 Gonzalez-Perez RR, Xu Y, Guo S, Watters A, Zhou W and Leibovich SJ (2010) Leptin upregulates UVEGF in breast cancer via canonical and non-canonical signalling pathways and NFkappaB/HIF-1alpha activation. *Cell Signal* **22**, 1350–1362.

15 Vadacca M, Zardi EM, Margiotta D, Rigon A, Cacciapaglia F, Arcarese L, Buzzulini F, Amoroso A and Afeltra A (2013) Leptin, adiponectin and vascular stiffness parameters in women with systemic lupus erythematosus. *Intern Emerg Med* **8**, 705–712.

16 Tian G, Liang JN, Wang ZY and Zhou D (2014) Emerging role of leptin in rheumatoid arthritis. *Clin Exp Immunol* **177**, 557–570.

17 Xiong RB, Li Q, Wan WR, Guo JQ, Luo BD and Gan L (2014) Effects and mechanisms of vitamin A and vitamin E on the levels of serum leptin and other related cytokines in rats with rheumatoid arthritis. *Exp Ther Med* **8**, 499–504.

18 Ghasemi A, Hashemy SI, Aghaei M and Panjehpour M (2017) RhoA/rock pathway mediates leptin-induced upa expression to promote cell invasion in ovarian cancer cells. *Cell Signal* **32**, 104–114.

19 Lanier V, Gillespie C, Leffers M, Daleybrown D, Milner J, Lipsey C, Webb N, Anderson LM, Newman G, Waltenberger J et al. (2016) Leptin-induced transphosphorylation of vascular endothelial growth factor receptor increases notch and stimulates endothelial cell angiogenic transformation. *Int J Biochem Cell Biol* **79**, 139–150.

20 Elshabrawy HA, Chen Z, Volin MV, Ravella S, Virupannavar S and Shahrrara S (2015) The pathogenic role of angiogenesis in rheumatoid arthritis. *Angiogenesis* **18**, 433–448.

21 Chien SY, Huang CY, Tsai CH, Wang SW, Lin YM and Tang CH (2016) Interleukin-1β induces fibroblast growth factor 2 expression and subsequently promotes endothelial progenitor cell angiogenesis in chondrocytes. *Clin Sci* **130**, 667–681.

22 Neumann E, Lefèvre S, Zimmermann B, Gay S and Müller-Ladner U (2010) Rheumatoid arthritis progression mediated by activated synovial fibroblasts. *Trends Mol Med* **16**, 458–468.

23 Lefèvre S, Knedla A, Tennie C, Kampmann A, Wunrau C, Dinser R, Korb A, Schnaker EM, Turner IH, Robbins PD et al. (2009) Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. *Nat Med* **15**, 1414–1420.

24 Xing R, Jin Y, Sun L, Yang L, Li C, Li Z, Liu X and Zhao J (2015) Interleukin-21 induces migration and invasion of fibroblast-like synoviocytes from patients with rheumatoid arthritis. *Clin Exp Immunol* **184**, 147–158.

25 Kayakabe K, Kuroiwa T, Sakurai N, Ikeuchi H, Kadiombo AT, Sakairi T, Matsumoto T, Maeshima A, Hiromura K and Nojima Y (2012) Interleukin-6 promotes destabilized angiogenesis by modulating angiopoietin expression in rheumatoid arthritis. *Rheumatology* **51**, 1571–1579.

26 Ando S and Catalano S (2012) The multifactorial role of leptin in driving the breast cancer microenvironment. *Nat Rev Endocrinol* **8**, 263–275.

27 Wei L, Li K, Pang X, Guo B, Su M, Huang Y, Wang N, Ji F, Zhong C, Yang J et al. (2016) Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2. *J Exp Clin Cancer Res* **35**, 166–175.

28 Cao H, Huang Y, Wang H, Pang X, Li K, Dang W, Tang H, Wei L, Su M, Tang C et al. (2016) Leptin promotes migration and invasion of breast cancer cells by stimulating IL-8 production in M2 macrophages. *Oncotarget* **7**, 65441–65453.

29 Scotce M, Conde J, Vuolteenaho K, Koskinen A, López V, Gómez-Reino J, Lago F, Moilanen E and Guallillo O (2013) Adipokines as drug targets in joint and bone disease. *Drug Discov Today* **19**, 241–258.

30 Gómez R, Conde J, Scotce M, Gómez-Reino JJ, Lago F and Guallillo O (2011) What’s new in our understanding of the role of adipokines in rheumatic diseases? *Nat Rev Rheumatol* **7**, 528–536.

31 Xibill@friedmann D, Bustosbahena C, Hernándezgónora S, Burgosvargus R and Montielhernández JL (2010) Two-year follow-up of plasma leptin and other cytokines in patients with rheumatoid arthritis. *Ann Rheum Dis* **69**, 930–931.

32 Brill C, Scheuer T, Bührer C, Endesfelder S and Schmitz T (2017) Oxygen impairs oligodendroglial development via oxidative stress and reduced expression of hif-1α. *Sci Rep* **7**, 43000.

33 Liu D, Zhang R, Wu J, Yu Y, Yin X, Cheng Y, Wu J, Feng C, Luo Y and Zhang J (2017) Interleukin-17A promotes esophageal adenocarcinoma cell invasiveness through ROS-dependent NF-κB-mediated MMP-2/9 activation. *Oncol Rep* **37**, 1779–1785.

34 Semenza GL (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. *Oncogene* **29**, 625–634.
35 Kaufmann J, Feist E, Roske AE and Schmidt WA (2013) Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. *Clin Rheumatol* **32**, 1347–1355.

36 Li S, Wu Z, Li L and Liu X (2016) Interleukin-6 (IL-6) receptor antagonist protects against rheumatoid arthritis. *Med Sci Monit* **22**, 2113–2118.

37 Diehl SA, Schmidlin H, Nagasawa M, van Haren SD, Kwakkenbos MJ, Yasuda E, Beaumont T, Scheeren FA and Spits H (2008) STAT3-mediated up-regulation of Blimp1 is coordinated with BCL6 down-regulation to control human plasma cell differentiation. *J Immunol* **180**, 4805–4815.